Pfizer (PFE) Deep Value Analysis: Why This Pharma Giant Is a Steal at $27
Pfizer might be the most hated stock on Wall Street right now. After the COVID vaccine boom faded, the stock has fallen over 50% from its highs. Most analysts have moved on.
That's exactly when value investors should be paying attention.
The Numbers Don't Lie
| Metric | Pfizer (PFE) | Graham Max |
|---|---|---|
| Market Price | $26.80 | — |
| Graham Number | $38.90 | — |
| P/E Ratio | 10.2 | ≤ 15 ✅ |
| P/B Ratio | 1.5 | ≤ 1.5 ✅ |
| Dividend Yield | 6.1% | > 0% ✅ |
| Current Ratio | 2.1 | > 2.0 ✅ |
| Margin of Safety | 36.3% | > 25% ✅ |
Pfizer passes every single one of Graham's defensive investor criteria. That's rare.
Why the Market Is Wrong
The market is pricing Pfizer for permanent decline. The narrative goes: COVID revenue dried up, the pipeline is weak, and nothing will replace Comirnaty/Paxlovid.
We disagree. Here's what the bears are missing:
1. The Pipeline Is Loaded
Pfizer has 113 programs in clinical development, with 37 in Phase 3 or registration. Key catalysts:
- Danuglipron (oral GLP-1 for obesity) — Phase 3 data expected 2026
- Elrexfio (multiple myeloma) — rapid share gains
- Abrysvo (RSV vaccine) — first-mover advantage
2. The Seagen Acquisition
The $43B Seagen deal gives Pfizer a world-class oncology pipeline. ADC (antibody-drug conjugate) technology is the future of cancer treatment. This acquisition alone could be worth more than the current stock price in 5 years.
3. Cost Cutting
Pfizer is targeting $4.5B in cost savings by 2027. That flows directly to the bottom line and supports the dividend.
Our Valuation
Using a conservative DCF model:
- Revenue CAGR: 3% (well below consensus)
- Operating margin: 28% (near current levels)
- Discount rate: 10%
- Terminal growth: 2%
Fair value: $42.10 — a 57% upside from current prices.
Even in a bear case (flat revenue, margin compression), we get fair value around $32 — still 20% upside.
The Dividend Safety Net
At $1.68 per share annually, Pfizer's dividend yields 6.1%. The payout ratio is about 62% of free cash flow, meaning it's well-covered. You're essentially getting paid a 6% return to wait for the market to come to its senses.
Our Rating: Strong Buy
Pfizer at $27 is a classic Graham-style deep value opportunity. You're buying a diversified pharma giant with a loaded pipeline at 10x earnings and collecting a 6% dividend.
Target price: $42.10 Margin of safety: 36.3% Rating: Strong Buy
Disclaimer: This is not financial advice. Always do your own research.
Get Picks Like This Every Tuesday
Join 10,000+ value investors getting our best undervalued stock picks, Graham Number breakdowns, and dividend analysis — free.
Get Our Best Stock Picks — Free
Join 10,000+ value investors. Get our top undervalued stock picks, Graham-style analysis, and dividend recommendations delivered to your inbox every week.
No spam, ever. Unsubscribe anytime.